Cyclin D2 is overexpressed in proliferation centers of chronic lymphocytic leukemia/small lymphocytic lymphoma

Cancer Science

Volumn 102, Issue 11, 2011, Pages 2103-2107

  Igawa, Takuro ^a   Sato, Yasuharu ^a   Takata, Katsuyoshi ^a   Fushimi, Soichiro ^a   Tamura, Maiko ^a   Nakamura, Naoya ^b   Maeda, Yoshinobu ^a   Orita, Yorihisa ^a   Tanimoto, Mitsune ^a   Yoshino, Tadashi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D2; CYCLIN D3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; PROTEIN P15; PROTEIN P16; PROTEIN P18; PROTEIN P27;

ADULT; AGED; ARTICLE; CANCER PATIENT; CCND2 GENE; CELL CYCLE REGULATION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTOMA; MALE; MANTLE CELL LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY MECHANISM; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; CYCLIN D2; CYCLINS; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPH NODES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NF-KAPPA B; PALATINE TONSIL; UP-REGULATION; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 80054969575     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02046.x     Document Type: Article

References (49)

1. 1 phase progression: cycling on cue. Cell 1994; 79: 551-5.
2. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9: 153-66.
3. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol 1996; 8: 805-14.
4. Suzuki R, Kuroda H, Komatsu H et al. Selective usage of D-type cyclins in lymphoid malignancies. Leukemia 1999; 13: 1335-42.
5. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther 2002; 1: 226-31.
6. Yatabe Y, Suzuki R, Tobinai K et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 2000; 95: 2253-61.
7. Fu K, Weisenburger DD, Greiner TC et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005; 106: 4315-21.
8. Mozos A. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2010; 95: 1620.
9. Teramoto N, Pokrovskaja K, Szekely L et al. Expression of cyclin D2 and D3 in lymphoid lesions. Int J Cancer 1999; 81: 543-50.
10. Metcalf RA, Zhao SC, Anderson MW et al. Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. Mod Pathol 2010; 23: 420-33.
11. Chiorazzi N, Rai KR, Ferrarini M. Mechanisms of disease: chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-15.
12. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V-H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-54.
13. Wiestner A, Rosenwald A, Barry TS et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944-51.
14. Admirand JH, Knoblock RJ, Coombes KR et al. Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. Mod Pathol 2010; 23: 1518-23.
15. Delmer A, Ajchenbaumcymbalista F, Tang RP et al. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 1995; 85: 2870-6.
16. Decker T, Schneller F, Hipp S et al. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia 2002; 16: 327-34.
17. Kosmaczewska A, Ciszak L, Szteblich A et al. Is cyclin D2 a marker of B-CLL cell activation? Oncol Res 2009; 18: 127-31.
18. Benezra J, Burke JS, Swartz WG et al. Small lymphocytic lymphoma: a clinicopathologic analysis of 268 cases. Blood 1989; 73: 579-87.
19. Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 2008; 26: 4497-503.
20. Gine E, Martinez A, Villamor N et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 2010; 95: 1526-33.
21. Cobo F, Martinez A, Pinyol M et al. Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia. Leukemia 2002; 16: 1028-34.
22. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-56.
23. Carreras J, Villamor N, Colomo L et al. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol 2005; 205: 507-13.
24. Del Poeta G, Maurillo L, Venditti A et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001; 98: 2633-9.
25. Deboer CJ, Schuuring E, Dreef E et al. Cyclin D1 protein-analysis in the diagnosis of mantle cell lymphoma. Blood 1995; 86: 2715-23.
26. O'Malley DP, Vance GH, Orazi A. Chronic lymphocytic leukemia/small lymphocytic lymphoma with trisomy 12 and focal cyclin D1 expression: a potential diagnostic pitfall. Arch Pathol Lab Med 2005; 129: 92-5.
27. Solvason N, Wu WW, Parry D et al. Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. Int Immunol 2000; 12: 631-8.
28. Mayr C, Speicher MR, Kofler DM et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006; 107: 742-51.
29. Qian L, Gong J, Liu J, Broome JD, Koduru PRK. Cyclin D2 promoter disrupted by t(12;22)(p13;q11.2) during transformation of chronic lymphocytic leukaemia to non-Hodgkin's lymphoma. Br J Haematol 1999; 106: 477-85.
30. Chiles TC. Regulation and function of cyclin D2 in B lymphocyte subsets. J Immunol 2004; 173: 2901-7.
31. Hewamana S, Lin TT, Rowntree C et al. Rel A is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 763-9.
32. Pepper C, Hewamana S, Brennan P, Fegan C. NF-kappa B as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. Future Oncol 2009; 5: 1027-37.
33. Brooks AR, Shiffman D, Chan CS, Brooks EE, Milner PG. Functional analysis of the human cyclin D2 and cyclin D3 promoters. J Biol Chem 1996; 271: 9090-9.
34. Grumont RJ, Strasser A, Gerondakis S. B cell growth is controlled by phosphatidylinosotol 3-kinase-dependent Rel/NF-kappa B regulated induction of c-myc transcription. Mol Cell 2002; 10: 1283-94.
35. Lee HY, Arsura M, Wu M, Duyao M, Buckler AJ, Sonenshein GE. Role of rel-related factors in control of c-myc gene-transcription in receptor-mediated apoptosis of the murine B-cell WEHI-231 line. J Exp Med 1995; 181: 1169-77.
36. Bouchard C, Thieke K, Maier A et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J 1999; 18: 5321-33.
37. Coller HA, Grandori C, Tamayo P et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA 2000; 97: 3260-5.
38. Danilov AV, Danilova OV, Brown JR, Rabinowitz A, Klein AK, Huber BT. Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia. Exp Hematol 2010; 38: 1167-77.
39. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002; 1602: 73-87.
40. Lee J, Kim SS. The function of p27(KIP1) during tumor development. Exp Mol Med 2009; 41: 765-71.
41. Staller P, Peukert K, Kiermaier A et al. Repression of p15(INK4b) expression by Myc through association with Miz-1. Nat Cell Biol 2001; 3: 392-9.
42. Nakamura N, Kuze T, Hashimoto Y et al. Analysis of the immunoglobulin heavy chain gene variable region of 101 cases with peripheral B cell neoplasms and B cell chronic lymphocytic leukemia in the Japanese population. Pathol Int 1999; 49: 595-600.
43. Deglesne PA, Chevallier N, Letestu R et al. Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression. Cancer Res 2006; 66: 7158-66.
44. Del Principe MI, Del Poeta G, Buccisano F et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 2006; 108: 853-61.
45. Ibrahim S, Keating M, Do KA et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98: 181-6.
46. Deaglio S, Vaisitti T, Aydin S, Ferrero E, Malavasi F. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006; 108: 1135-44.
47. Chen L, Widhopf G, Huynh L et al. Expression of ZAP-70 is associated with increased B cell receptor signaling in chronic lymphocytic leukemia. Blood 2002; 100: 4609-14.
48. Efremov DG, Gobessi S, Longo PG. Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells. Autoimmun Rev 2007; 7: 102-8.
49. Deaglio S, Vaisitti T, Malavasi F. CD38 ligation in B-chronic lymphocytic leukemia cells induces sequential tyrosine phosphorylation of ZAP70, PLC-gamma 2 and ERK1/2 proteins (Abstract). Blood 2004; 104: A274-5.